A citation-based method for searching scientific literature

Martha E Stewart, Anne T Knisely, Mackenzie W Sullivan, Kari L Ring, Susan C Modesitt. Gynecol Oncol Rep 2019
Times Cited: 5

List of co-cited articles
25 articles co-cited >1

Times Cited
  Times     Co-cited

Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Mark E Sherman, Marion Piedmonte, Phuong L Mai, Olga B Ioffe, Brigitte M Ronnett, Linda Van Le, Iouri Ivanov, Maria C Bell, Stephanie V Blank, Paul DiSilvestro,[...]. J Clin Oncol 2014

Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
Mae Zakhour, Yael Danovitch, Jenny Lester, B J Rimel, Christine S Walsh, Andrew J Li, Beth Y Karlan, Ilana Cass. Gynecol Oncol 2016

Characteristics of Lynch syndrome associated ovarian cancer.
J M Woolderink, G H De Bock, J A de Hullu, H Hollema, R P Zweemer, B F M Slangen, K N Gaarenstroom, M van Beurden, H C van Doorn, R H Sijmons,[...]. Gynecol Oncol 2018

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
Kelly L Bolton, Georgia Chenevix-Trench, Cindy Goh, Siegal Sadetzki, Susan J Ramus, Beth Y Karlan, Diether Lambrechts, Evelyn Despierre, Daniel Barrowdale, Lesley McGuffog,[...]. JAMA 2012

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Valérie Bonadona, Bernard Bonaïti, Sylviane Olschwang, Sophie Grandjouan, Laetitia Huiart, Michel Longy, Rosine Guimbaud, Bruno Buecher, Yves-Jean Bignon, Olivier Caron,[...]. JAMA 2011

Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
Michael J Callahan, Christopher P Crum, Fabiola Medeiros, David W Kindelberger, Julia A Elvin, Judy E Garber, Colleen M Feltmate, Ross S Berkowitz, Michael G Muto. J Clin Oncol 2007

Ovarian cancer in Lynch syndrome; a systematic review.
J M Helder-Woolderink, E A Blok, H F A Vasen, H Hollema, M J Mourits, G H De Bock. Eur J Cancer 2016

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
Susan M Domchek, Tara M Friebel, Judy E Garber, Claudine Isaacs, Ellen Matloff, Rosalind Eeles, D Gareth Evans, Wendy Rubinstein, Christian F Singer, Stephen Rubin,[...]. Breast Cancer Res Treat 2010

Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes.
Claire Thompson, Ciara McCormick, Waseem Kamran, Ciaran O'Riain, Lucy Norris, David Gallagher, Noreen Gleeson. Ir J Med Sci 2018

Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Fatima Laki, Youlia M Kirova, Pascale This, Corinne Plancher, Bernard Asselain, Xavier Sastre, Dominique Stoppa-Lyonnet, Remy Salmon. Cancer 2007

Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy.
Carolin Poon, Simon Hyde, Peter Grant, Marsali Newman, Kerryn Ireland Jenkin. Int J Gynecol Cancer 2016

Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
Enzo Ricciardi, Federica Tomao, Giovanni Aletti, Luca Bazzurini, Luca Bocciolone, Sara Boveri, Fabio Landoni, Maria Teresa Lapresa, Matteo Maruccio, Gabriella Parma,[...]. Anticancer Res 2017

Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Julie D Lamb, Rochelle L Garcia, Barbara A Goff, Pamela J Paley, Elizabeth M Swisher. Am J Obstet Gynecol 2006

High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
Jane E Hirst, Gregory B Gard, Kirsty McIllroy, David Nevell, Michael Field. Int J Gynecol Cancer 2009

Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
Marjanka J J M Mingels, Thijs Roelofsen, Jeroen A W M van der Laak, Joanne A de Hullu, Maaike A P C van Ham, Leon F A G Massuger, Johan Bulten, Mijke Bol. Gynecol Oncol 2012

Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
F Blok, S Dasgupta, W N M Dinjens, E M Roes, H J van Beekhuizen, P C Ewing-Graham. Gynecol Oncol 2019

Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
L Minig, S Cabrera, R Oliver, A Couso, M J Rubio, S Iacoponi, M B Martin-Salamanca, S Carballo-Rastrilla, J M Cádenas-Rebollo, A García-Garcia,[...]. Clin Transl Oncol 2018

Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
C Bethan Powell, Lee-may Chen, Jane McLennan, Beth Crawford, Charles Zaloudek, Joseph T Rabban, Dan H Moore, John Ziegler. Int J Gynecol Cancer 2011

Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).
Stephanie L Wethington, Kay J Park, Robert A Soslow, Noah D Kauff, Carol L Brown, Fanny Dao, Ebunoluwa Otegbeye, Yukio Sonoda, Nadeem R Abu-Rustum, Richard R Barakat,[...]. Int J Gynecol Cancer 2013

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
Fabiola Medeiros, Michael G Muto, Yonghee Lee, Julia A Elvin, Michael J Callahan, Colleen Feltmate, Judy E Garber, Daniel W Cramer, Christopher P Crum. Am J Surg Pathol 2006

Surfing the p53 network.
B Vogelstein, D Lane, A J Levine. Nature 2000

The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Magali Olivier, Anita Langerød, Patrizia Carrieri, Jonas Bergh, Sigrid Klaar, Jorunn Eyfjord, Charles Theillet, Carmen Rodriguez, Rosette Lidereau, Ivan Bièche,[...]. Clin Cancer Res 2006

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.
Rebecca Kristeleit, Geoffrey I Shapiro, Howard A Burris, Amit M Oza, Patricia LoRusso, Manish R Patel, Susan M Domchek, Judith Balmaña, Yvette Drew, Lee-May Chen,[...]. Clin Cancer Res 2017

Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.
K H Lu, J E Garber, D W Cramer, W R Welch, J Niloff, D Schrag, R S Berkowitz, M G Muto. J Clin Oncol 2000

Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Timothy R Rebbeck, Tara Friebel, Theresa Wagner, Henry T Lynch, Judy E Garber, Mary B Daly, Claudine Isaacs, Olufunmilayo I Olopade, Susan L Neuhausen, Laura van 't Veer,[...]. J Clin Oncol 2005

Double-strand break end resection and repair pathway choice.
Lorraine S Symington, Jean Gautier. Annu Rev Genet 2011

Shared heritability and functional enrichment across six solid cancers.
Xia Jiang, Hilary K Finucane, Fredrick R Schumacher, Stephanie L Schmit, Jonathan P Tyrer, Younghun Han, Kyriaki Michailidou, Corina Lesseur, Karoline B Kuchenbaecker, Joe Dennis,[...]. Nat Commun 2019

PARP Inhibitors for the Treatment of Ovarian Cancer.
Laura Cortesi, Angela Toss, Iole Cucinotto. Curr Cancer Drug Targets 2018

A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.
Carolyn Y Fang, Carol Cherry, Karthik Devarajan, Tianyu Li, John Malick, Mary B Daly. Gynecol Oncol 2009

Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.
Leo Reap, Samira Ahsan, Monique Saleh. Clin Breast Cancer 2018

Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Steven J Skates, Mark H Greene, Saundra S Buys, Phuong L Mai, Powel Brown, Marion Piedmonte, Gustavo Rodriguez, John O Schorge, Mark Sherman, Mary B Daly,[...]. Clin Cancer Res 2017

Better survival rates in patients with MLH1-associated hereditary colorectal cancer.
R Sankila, L A Aaltonen, H J Järvinen, J P Mecklin. Gastroenterology 1996

BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Marie Soegaard, Susanne Kruger Kjaer, Mark Cox, Eva Wozniak, Estrid Høgdall, Claus Høgdall, Jan Blaakaer, Ian J Jacobs, Simon A Gayther, Susan J Ramus. Clin Cancer Res 2008

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
Nienke M van der Velde, Marian J E Mourits, Henriëtte J G Arts, Jacob de Vries, Beike K Leegte, Grieteke Dijkhuis, Jan C Oosterwijk, Geertruida H de Bock. Int J Cancer 2009

Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
Adam N Rosenthal, Lindsay Fraser, Ranjit Manchanda, Philip Badman, Susan Philpott, Jessica Mozersky, Richard Hadwin, Fay H Cafferty, Elizabeth Benjamin, Naveena Singh,[...]. J Clin Oncol 2013

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
Timothy R Rebbeck, Henry T Lynch, Susan L Neuhausen, Steven A Narod, Laura Van't Veer, Judy E Garber, Gareth Evans, Claudine Isaacs, Mary B Daly, Ellen Matloff,[...]. N Engl J Med 2002

No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
B B J Hermsen, R I Olivier, R H M Verheijen, M van Beurden, J A de Hullu, L F Massuger, C W Burger, C T Brekelmans, M J Mourits, G H de Bock,[...]. Br J Cancer 2007

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
Robert J Morgan, Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, Kian Behbakht, Lee-May Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo,[...]. J Natl Compr Canc Netw 2016

Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.
Lisa Golmard, Laurent Castéra, Sophie Krieger, Virginie Moncoutier, Khadija Abidallah, Henrique Tenreiro, Anthony Laugé, Julien Tarabeux, Gael A Millot, André Nicolas,[...]. Eur J Hum Genet 2017

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, Yiping Zhang, Jiuping Ji, Shunichi Takeda, Joel Morris, Beverly Teicher, James H Doroshow, Yves Pommier. Mol Cancer Ther 2014

Whole genomes redefine the mutational landscape of pancreatic cancer.
Nicola Waddell, Marina Pajic, Ann-Marie Patch, David K Chang, Karin S Kassahn, Peter Bailey, Amber L Johns, David Miller, Katia Nones, Kelly Quek,[...]. Nature 2015

p53 Family and Cellular Stress Responses in Cancer.
Johanna Pflaum, Sophie Schlosser, Martina Müller. Front Oncol 2014

Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Ian J Jacobs, Usha Menon, Andy Ryan, Aleksandra Gentry-Maharaj, Matthew Burnell, Jatinderpal K Kalsi, Nazar N Amso, Sophia Apostolidou, Elizabeth Benjamin, Derek Cruickshank,[...]. Lancet 2016

Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.